This is a new guideline from NICE on idelalisib use in chronic lymphocytic leukaemia. Idelalisib is likely to be secondary care prescribed, but I felt it was worthwhile knowing about as it is a new type of drug and we will probably see patients on it.
Idelalisib is an oral drug and will be used in combination with rituximab infusions. It is a 'first-in-class' drug which inhibits enzymes involved in cell proliferation, death and migration.
Among other side-effects, it can raise transaminases, triglycerides and can cause neutropenia.
Latest posts by Louise Hudman (see all)
- Nice | Who should we be testing for cirrhosis? - October 3, 2016
- Nice | Non-alcoholic fatty liver disease NAFLD - August 26, 2016
- Evolocumab and Alirocumab for treating dyslipidaemia - August 25, 2016